UPDATE: RBC Capital Starts FibroGen (FGEN) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Stifel Starts FibroGen (FGEN) at Buy
December 9, 2014 7:39 AM ESTStifel initiated coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $39.00.
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $28.00 yesterday.
... MoreGoldman Sachs Starts FibroGen (FGEN) at Buy
December 9, 2014 7:38 AM ESTGoldman Sachs initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $32.00.
Analyst Terence Flynn said, "Based on the Roxa Phase 2 data we see three potential benefits over injectable ESAs potential to improve safety (focus will be on... More
William Blair Starts FibroGen (FGEN) at Outperform
December 8, 2014 7:42 AM ESTWilliam Blair initiated coverage on FibroGen (NASDAQ: FGEN) with an Outperform rating.
Analyst John Sonnier estimated that the company would generate revenue of $136 million in 2014 and $191 million in 2015, and believes the company has sufficient capital to sustain itself for at least two years.
"Our bullish investment outlook on FibroGen is based on a variety of factors," Sonnier said. "These include the strength of lead product candidates roxadustat, which is... More
